1. Home
  2. SMX vs NEUP Comparison

SMX vs NEUP Comparison

Compare SMX & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SMX (Security Matters) Public Limited Company

SMX

SMX (Security Matters) Public Limited Company

HOLD

Current Price

$15.65

Market Cap

19.7M

Sector

Technology

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

N/A

Current Price

$3.46

Market Cap

23.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SMX
NEUP
Founded
N/A
1996
Country
Ireland
United States
Employees
19
8
Industry
Industrial Machinery/Components
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
19.7M
23.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SMX
NEUP
Price
$15.65
$3.46
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
44.7K
97.5K
Earning Date
04-23-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.75
$3.19
52 Week High
$490.00
$21.31

Technical Indicators

Market Signals
Indicator
SMX
NEUP
Relative Strength Index (RSI) 57.50 31.65
Support Level $15.39 $3.19
Resistance Level $17.72 $4.58
Average True Range (ATR) 1.89 0.31
MACD -0.07 -0.04
Stochastic Oscillator 66.38 21.33

Price Performance

Historical Comparison
SMX
NEUP

About SMX SMX (Security Matters) Public Limited Company

SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: